Navigation Links
Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
Date:5/1/2008

PHILADELPHIA, May 1 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention Deficit Hyperactivity Disorder (ADHD) treatments, lisdexamfetamine dimesylate, methylphenidate transdermal system and the investigational non-stimulant treatment under FDA review, guanfacine extended release, at the American Psychiatric Association (APA) annual meeting to be held May 3rd to 8th in Washington, D.C.

"Shire is committed to the advancement of ADHD research, and we are pleased to be presenting the efficacy and safety results from several studies of our ADHD treatments," said Gwendolyn Niebler, Vice President of Global Medical Affairs at Shire. "We believe the physician community will find the lisdexamfetamine dimesylate, methylphenidate transdermal system and guanfacine extended release study findings to be presented at APA a relevant contribution to the growing body of research on our ADHD treatment options."

A summary of the key scientific presentations is provided below. Information about these data presentations mentioned in this release is embargoed until the respective presentation sessions have taken place at the meeting.

Lisdexamfetamine Dimesylate:

May 7, 2008; 12:00 p.m. ET

Lisdexamfetamine Dimesylate Treatment in Children Diagnosed with ADHD:

Parental Impressions and Experiences

APA Poster Presentation # NR6-025

May 8, 2008; 11:00 a.m. ET

Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults with ADHD

APA Oral Presentation Session # 28

Methylphenidate Transdermal System:

May 7, 2008; 12:00 p.m. ET

Long-Term Treatment Effects of the Methylphenidate Transdermal System in

Boys and Girls with ADHD

APA Poster Presentation # NR6-018

Guanfacine Extended Release:

May 7, 2008; 12:00 p.m. ET

Guanfacine Extended Release:
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
2. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
3. Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers
4. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
5. Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
6. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
7. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
10. Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008
11. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...WICK,N.J.,Nov.25/PRNewswire/--SwissrayInternationa...hy( ddR )systems,announcedtodaythatitsoperationsha...viewtowardsgrowingSwissray,smedicalimagingbrand.Th...ty,aswellascontractsandinventory.After25yearsofsuc...eloftechnologicaladvancementswithstableandsteadygr...
(Date:11/25/2009)...Nov.25/PRNewswire-FirstCall/--NuVasive,Inc.(Nasdaq...roductsforminimallydisruptivesurgicaltreatmentsfor...llonMonday,November30,2009,at5:30p.m.ET/2:30p.m.PT...toreimbursementfortheCompany,sproductsandwillinclu...danswersession.Thedial-innumbersare1-877-407-4018f...
(Date:11/25/2009)...ov.25/PRNewswire/--Reportlinker.comannouncesthatan..., PainManagement-GlobalTrends ,, http:/...lobal-Trends.html ,, Widespreadavailabilityofg...eadventofnewdrugshaveacceleratedthepaceofgrowthint...sementstructurecontinuetoshapedemandforservices,dr...
Breaking Medicine Technology:Swissray International Announces New Ownership 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3Reportlinker Adds Pain Management - Global Trends 2Reportlinker Adds Pain Management - Global Trends 3Reportlinker Adds Pain Management - Global Trends 4Reportlinker Adds Pain Management - Global Trends 5Arpida Reports Interim Results For Six Months to 30 June 2009 13631 1Arpida Reports Interim Results For Six Months to 30 June 2009 13631 2Detecting bias in the reporting of clinical trials 54860 1Researchers boost production of biofuel that could replace gasoline 9616 1Researchers boost production of biofuel that could replace gasoline 9616 2
...n highly potent DPP-4 inhibitor, possessing Ki of ...ph Pharmaceuticals,Inc., a privately held drug di... the results of its potent, smart DPP-4 inhibitor,...erican Diabetes,Association meeting in Chicago, Il...remely long acting, potent inhibitor of DPP-4 and,...
...Change Reported Unlike What Is Commonly Seen In,In...FirstCall/ -- Novo Nordisk,today announced results...ty and efficacy of insulin Levemir(R) (insulin det...2 diabetes were able,to adjust their own dosage of...r, comparable to dosing adjusted by their primary ...
Other Medicine Technology:Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4,Inhibitor, ARI-2243, at the ADA 2Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4,Inhibitor, ARI-2243, at the ADA 3Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4,Inhibitor, ARI-2243, at the ADA 4New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 2New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 3New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 4New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 5
(Date:11/25/2009)...,, EDINA,Minn.,Nov.25/PRNewswire-USNewswire/...dentist.Butachiropractorcanalsogivepatientsthehelp...hichiswhereyourjaw(mandible)contacts/connectswithy...sassociatedwithTMJdysfunctionarepainwithchewing,cl...ausedfromTMJdysfunctionincluding:headaches,fatigue...
(Date:11/25/2009)...,, EMERYVILLE,Calif.,Nov.25/PRNewswire-First...dayannouncedthatthecompanywillhosttwoinvestorevent...r7,2009-9:00a.m.CT/10:00a.m.ET ,, Principalin...carfilzomibinrelapsedand/orrefractorymultiplemyelo...ASH)AnnualMeetingandExpositioninNewOrleans,LA.Thet...
(Date:11/25/2009)...,, TORONTO,Nov.25/PRNewswire/-SentinelleMedi...ancedvisualizationsoftwarelaunchesasuiteofnewleadi...gingsoftwareplatformatthisyear,sRadiologicalSociet...-Dec.5,2009(Booth5800,HallA).Theapplicationslevera...sspecializedMRIimagingcoilsandsupportmultipleimagi...
(Date:11/25/2009)...,, SILVERSPRING,Md.,Nov.25/PRNewswire-USNews...FDA,sCenterforDrugEvaluationandResearch,titled"ADi...,"appearsintheNov.26,2009issueofTheNewEnglandJourn...cgi-bin/prnh/20090824/FDALOGO ) ,, Inthearticle...naccesstopainmedicationforthosewhoneeditandmanagin...
(Date:11/25/2009)...,, SANFRANCISCO,Nov.25/PRNewswire/--TheBayAr...first Winter Spare the Air Alert for...acturedfirelogsoranyothersolidfuel,bothindoorsando...nhealthyairqualitytomorrow,"saidJackBroadbent,exec...sidentstorespectthehealthoftheirneighborsandfellow...
Breaking Medicine News(10 mins):Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 3Health News:Winter Spare the Air Alert in Effect for Thursday, November 26, 2009 2
...y Over Estimated A UK doctor, and a leading exp...s in children are being overstated, leading to unn...m the University of Newcastle upon Tyne said there...ng in the British Medical Journal, he said that ov...
...ys that breastfeeding in the US depends on what cl...fessional backgrounds// are allowed to breastfeed ... "I feel like I had to choose between feeding...r breaks behind a fridge or the toilet in order to...
...s show that drug deaths in Scotland have dropped t... drugs in Scotland in 2005 compared with 356 in 20...e is a tragedy and reminds us that drug abuse is a...ures for drug-related deaths have fallen but we ca...
...rpses in polythene bags and burying people who hav...theastern Indian state of Mizoram has outraged peo...king to find people in some parts of the state pac... with HIV/AIDS Society, told IANS. With a l...
...a special committee to check cases of polio that h...first week of August the country reported 155 case...tar Pradesh, the country's most populous state. ...h Minister Ambumani Ramadoss told IANS on the side...
...to doing well in school because your child will be...ile doing homework.// While this is common sense, ...an be complex; and the rewards for treatment can e...Robin A. Dyleski, MD director of Pediatric Otolary...
Other Medicine News:Health News:Strange Burial Practice Followed for People Affected by HIV/AIDS 2
...ed on the TrueView II design, a new generation of ...roscopy is available. The new telescope class is f...us advanced fibre technology. For the surgeon, the...t colour reproduction, high resolution and ergonom...
Small Joint Arthroscopes
...AR Technology, which transforms traditional ultras...hnology dramatically reduces the amount of phaco e...full ultrasound cutting efficiency. Surgeons hav...d efficiently to the phaco tip, in a phenomenon th...
AMO Vitrax (sodium hyaluronate) viscoelastic solution
Medicine Products: